Stage II KRAS Non-Small Cell Lung Cancer: Camila's Patient Story

Patient Info: Camila Bermúdez García, Female, Under 40 | Stage II

Biomarkers: KRAS mutation

Camila is preparing to apply to medical school and advocates for young adults affected by lung cancer in Puerto Rico while continuing to process the effects of diagnosis and treatment.

Delayed adrenal insufficiency after lung cancer immunotherapy

Patient Info: Anonymized, male, 60s | Stage II

Imaging and bronchoscopy in November 2024 showed no lung-cancer recurrence or metastasis. By June 2026, he had not experienced another adrenal crisis while continuing hormone replacement.

PubMed CentralRead more →

Stage II KRAS Lung Adenocarcinoma: Roy's Survivor Story

Patient Info: Roy, Male, 50s | Stage II

Biomarkers: KRAS

As of May 2026, Roy described being cancer-free/in remission, back to flying professionally, and strong enough to complete his 5th marathon at the Boston Marathon.

The Patient StoryRead more →

No recurrence 2 years after surgery for Stage II lung adenocarcinoma

Patient Info: Anonymized, Male, 50s | Stage II

At 2-year follow-up, he remained well with no local recurrence or distant metastasis.

PubMed CentralRead more →

Stage II Lung Cancer: Michelle's Patient Story

Patient Info: Michelle, Female | Stage II

Receiving ongoing adjuvant treatment after lung cancer first thought to be Stage I was upgraded to Stage IIB because 3 of 18 lymph nodes were positive.

The Patient StoryRead more →

Stage II EGFR Non-Small Cell Lung Cancer: Daniel's Patient Story

Patient Info: Daniel West, Male, 50s | Stage II

Biomarkers: EGFR positive

As of April 2026, Daniel had shown no evidence of active disease for more than 2 years, while remaining on daily osimertinib through June 2026 and receiving checkups and scans every 3 months for stable monitored lung nodules.

MD AndersonRead more →

Stage IIB lung adenocarcinoma: pembrolizumab-associated psoriasiform dermatitis resolved after stopping therapy

Patient Info: Anonymized, Male, 50s | Stage II

Biomarkers: PD-L1 status not reported in the available case text

Over 3 years of follow-up after stopping pembrolizumab, the psoriasiform dermatitis resolved completely and lung adenocarcinoma remained stable without radiologic or serologic recurrence.

PubMed CentralRead more →

Lung Cancer Treated With Sleeve Right Lower Lobectomy in COPD

Patient Info: Anonymized, male | Stage II

He remained disease-free through 28 months of follow-up.

PubMed CentralRead more →

Lung Cancer Treated With Sleeve Right Lower Lobectomy in COPD — Case 3

Patient Info: Anonymized, male | Stage II

He remained disease-free through 30 months of follow-up.

PubMed CentralRead more →

Lung Cancer Treated With Sleeve Right Lower Lobectomy in COPD — Case 4

Patient Info: Anonymized, male | Stage II

He had no lung-cancer recurrence and died from a cerebral hemorrhage 51 months after surgery.

PubMed CentralRead more →

KRAS G12C lung adenocarcinoma with hypertrophic pulmonary osteoarthropathy: no recurrence after lobectomy

Patient Info: Anonymized, Male, 50s | Stage II

Biomarkers: KRAS detected; PD-L1 <1%

At 1-year follow-up, there was no evidence of recurrence; pain, edema, grip strength, and periosteal thickening related to hypertrophic pulmonary osteoarthropathy improved after surgery.

PubMed CentralRead more →

Stage II EGFR Lung Cancer: Samantha's Patient Story

Patient Info: Samantha Vaughn, Female | Stage II

Biomarkers: EGFR mutation

Samantha had Stage II EGFR-mutated lung cancer removed surgically and was receiving post-operative daily Tagrisso through a clinical trial. As of June 2025, she reported clear results so far but remained on active targeted therapy.

The Patient StoryRead more →

Stage II Lung Squamous Cell Carcinoma Complicated by Immunotherapy-Induced Cutaneous Lupus

Patient Info: Anonymized, male, 60s | Stage II

Imaging showed a treatment response. After radical radiotherapy, camrelizumab was discontinued because of immune-mediated subacute cutaneous lupus, and the lung cancer was placed under active monitoring.

PubMed CentralRead more →

Stage II ALK Non-Small Cell Lung Cancer: Stephanie's Survivor Story

Patient Info: Stephanie, Female | Stage II

Biomarkers: ALK-rearranged

As of January 2025, Stephanie had clean scans and bloodwork for 3 years after Stage IIB ALK-positive lung adenocarcinoma treated with surgery, 4 rounds of chemotherapy, and ongoing daily targeted therapy.

The Patient StoryRead more →

Stage II ALK Lung Adenocarcinoma: Stephanie's Patient Story

Patient Info: Stephanie Williams, Female | Stage II

Biomarkers: ALK-rearranged

Stephanie had clean scans nearly 3 years after diagnosis but remained on daily ALK-targeted therapy to reduce recurrence risk.

The Patient StoryRead more →

Lung adenocarcinoma mimicking interstitial lung disease: Stage IIB diagnosis after VATS biopsy

Patient Info: Anonymized, Male, 50s | Stage II

Biomarkers: CK7-positive; CK20-positive; TTF-1-positive; CDX2-negative; no EGFR/ALK/ROS1/KRAS molecular results provided

As of January 2025, he had recovered from diagnostic VATS wedge resection/biopsies for reported Stage IIB lung adenocarcinoma and was referred for definitive oncology and pulmonology management.

PubMed CentralRead more →

Stage IIB squamous cell lung cancer: pathological complete response after chemo-immunotherapy and surgery

Patient Info: Anonymized, Male, 60s | Stage II

Biomarkers: PD-L1 >85%; P40-positive; TTF-1-negative; CEA 1.2 ng/mL; cytokeratin 19 fragments 1.7 ng/mL; pro-gastrin-releasing peptide 54 pg/mL

No recurrence for 1 year and 7 months without further treatment after transbronchoscopic resection, pembrolizumab-based chemoimmunotherapy, pneumonitis management, and sleeve resection showing pathological complete response.

PubMed CentralRead more →

Stage IIIA squamous lung cancer: surgery after nivolumab-related complications

Patient Info: Anonymized, Female, 70+ | Stage II

Biomarkers: PD-L1 TPS 99% before treatment; PD-L1 TPS 70% in postoperative hilar lymph node; TPOAb and TgAb normal during thyroiditis workup

As of January 2025, the patient had no recurrence 7 months after neoadjuvant nivolumab/carboplatin/paclitaxel and 5 months after thoracoscopic right upper lobectomy with lymph node dissection.

PubMed CentralRead more →

Recurrent Lung Adenocarcinoma Complicated by a Tracheopericardial Fistula

Patient Info: Anonymized, male, 70+ | Stage II

Biomarkers: No gene mutations identified on postoperative testing

He died during the June 2024 admission, about 7½ years after his November 2016 lung-cancer diagnosis, after massive hemoptysis occurred in the setting of a tracheopericardial fistula and recurrent cancer.

PubMed CentralRead more →

Stage II Lung Cancer: Att's Patient Story

Patient Info: Att Callahan, Female, 70+ | Stage II

As of July 2024, Att was receiving monthly post-surgery immunotherapy and scans every other month after clinical-trial chemoimmunotherapy and lobectomy, with doctors believing they had removed all visible cancer.

MD AndersonRead more →

Guillain-Barré syndrome after surgery for Stage II lung adenocarcinoma

Patient Info: Anonymized, Male, 70+ | Stage II

No lung-cancer recurrence was seen at follow-up after complete resection. His postoperative Guillain-Barré syndrome resolved within 3 months after immunoglobulin treatment and rehabilitation.

PubMed CentralRead more →

Stage II EGFR Non-Small Cell Lung Cancer: Daniel's Survivor Story

Patient Info: Daniel West, Male | Stage II

Biomarkers: EGFR alteration

At the latest report, Daniel had no evidence of active cancer; small lung nodules were being monitored without progression while he continued osimertinib.

Stage II lung adenocarcinoma with a fetal-type component treated with surgery

Patient Info: Anonymized, male, 70+ | Stage II

Biomarkers: PD-L1 negative; no alterations identified on Oncomine Dx testing

He was doing well without recurrence 8 months after surgery.

PubMed CentralRead more →

Stage II Lung Cancer: Ed's Survivor Story

Patient Info: Ed Ackerman, Male, 60s | Stage II

Follow-up tests and scans showed Ed was cancer-free after lung resection and 4 rounds of chemotherapy for Stage IIA lung cancer.

Cleveland ClinicRead more →